Back

Q&A

3 April 2025 (15:55 - 16:00)
Organised by: Logo
Congress Presentation Part of: From risk assessment to action: the role of icosapent ethyl in cardiovascular risk management Secondary Prevention Open Access ESC Preventive Cardiology 2025 European Association of Preventive Cardiology (EAPC)

4 More presentations in this session

Presentation thumbnail
Clinical Case Introduction
Professor V. Aboyans (Monaco, MC)
Slides Video
Presentation thumbnail
U-Prevent: a personalized approach to cardiovascular risk management
Doctor J. Dorresteijn (Utrecht, NL)
Slides
Presentation thumbnail
Understanding the clinical benefit of icosapent ethyl: insights from REDUCE-IT
Doctor H. Contractor (Manchester, GB)
Slides Video
Presentation thumbnail
Key takeaways: addressing residual cardiovascular risk with proven therapies
Professor G. De Ferrari (Turin, IT)
Slides Video

Access the full session

Session thumbnail
From risk assessment to action: the role of icosapent ethyl in cardiovascular risk management
Video

The Event

Event poster

ESC Preventive Cardiology 2025

3 April 2025 15:55 CET
You may be interested in
thumbnail
Congress Presentation
EAS Consensus on Lp(a) 2022- What to measure, in whom to measure, how to interpret and what to do - Q&A .
29 August 2022
thumbnail
Congress Session
Evolving treatment paradigms in heart failure: from SGLT2 inhibition to transthyretin stabilisation and beyond
20 May 2025
thumbnail
Congress Presentation
Cardiovascular risk reduction & hypertriglyceridemia: integrating the evidence
29 August 2025
thumbnail
Congress Presentation
Icosapent ethyl in clinical practice: the Spanish experience
29 August 2025

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources